ArticleTheranostics2020
PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 65 citations in OpenAlex.
- Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma.Frontiers in immunology · 2026Review
- SOX2 drives esophageal squamous carcinoma by reprogramming lipid metabolism and histone acetylation landscape.Nature communications · 2025Article
- Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality.Genes & diseases · 2025Review
- AKT1 as a therapeutic target for platinum-resistant SOX2 positive ovarian cancer cells.Scientific reports · 2025Article
- Overexpression of ornithine decarboxylase 1 mediates the immune-deserted microenvironment and poor prognosis in diffuse large B-cell lymphoma.Journal of the National Cancer Center · 2025Article
- B7-H7 knockdown suppresses the proliferation, metastasis, and drug resistance of B-cell non-Hodgkin lymphoma cells by inhibiting the PI3K/Akt pathway.Frontiers in oncology · 2025Article
- Prognostic marker Musashi-2 modulates DNA damage response and radioresistance in diffuse large B-cell lymphoma.Frontiers in cell and developmental biology · 2025Article
- Exosomes derived from BMSCs in osteogenic differentiation promote type H blood vessel angiogenesis through miR-150-5p mediated metabolic reprogramming of endothelial cells.Cellular and molecular life sciences : CMLS · 2024Article
- Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma.Molecular cancer therapeutics · 2024Article
- FKBP3 aggravates the malignant phenotype of diffuse large B-cell lymphoma by PARK7-mediated activation of Wnt/β-catenin signalling.Journal of cellular and molecular medicine · 2024Article
- Extranodal lymphoma: pathogenesis, diagnosis and treatment.Molecular biomedicine · 2023Review
- GSK3β-driven SOX2 overexpression is a targetable vulnerability in esophageal squamous cell carcinoma.Oncogene · 2023Article
- Control of SOX2 protein stability and tumorigenic activity by E3 ligase CHIP in esophageal cancer cells.Oncogene · 2023Article
- RNA-seq analysis reveals candidate genes associated with proliferation, invasion, and migration in BCL11A knockdown B-NHL cell lines.Annals of hematology · 2023Article
- Up-regulation of PUM1 by miR-218-5p promotes colorectal tumor-initiating cell properties and tumorigenesis by regulating the PI3K/AKT axis.Journal of gastrointestinal oncology · 2023Article
- In Silico Identification and Functional Characterization of Genetic Variations across DLBCL Cell Lines.Cells · 2023Article
- Unraveling the enigma of B cells in diffuse large B-cell lymphoma: unveiling cancer stem cell-like B cell subpopulation at single-cell resolution.Frontiers in immunology · 2023Article
- CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.Molecular cancer · 2022Article
- A novel DNA aptamer targeting lung cancer stem cells exerts a therapeutic effect by binding and neutralizing Annexin A2.Molecular therapy. Nucleic acids · 2022Article
- lncNBAT1/APOBEC3A is a mediator of HBX-induced chemoresistance in diffuse large B cell lymphoma cells.Molecular therapy. Nucleic acids · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 1 country.
Jianfeng ChenFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaowen GeDepartment of Pathology, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Wei ZhangFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Peipei DingFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yiqun DuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Qi WangFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Ling LiFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Lan FangShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Yujing SunFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Pingzhao ZhangFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yuzhen ZhouFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Long ZhangFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xinyue LvFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Luying LiFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xin ZhangFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Qunling ZhangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Kai XueDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Hongyu GuFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Qunying LeiFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Jiemin WongShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Weiguo HuFudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CNEast China Normal University · CNZhongshan Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Up to one-third of diffuse large B cell lymphoma (DLBCL) patients eventually develop resistance to R-CHOP regimen, while the remaining therapeutic options are limited. Thus, understanding the underlying mechanisms and developing therapeutic approaches are urgently needed.
Indexed as
AminopyridinesAnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBenzimidazolesCell DifferentiationCyclophosphamideDoxorubicinDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansIsoquinolinesLymphoma, Large B-Cell, DiffuseMiceMice, SCIDabemaciclibAKT1 protein, humanAminopyridinesAZD4547BenzamidesBenzimidazolesCyclophosphamideDoxorubicinduvelisibIsoquinolinesNeoplasm ProteinsPhosphatidylinositol 3-KinasesPiperazinesPrednisoneProtein Kinase InhibitorsProto-Oncogene Proteins c-aktPurinesPyrazolesRituximabSOX2 protein, humanSOXB1 Transcription FactorsTranscription FactorsVincristinecancer stem-like cellsDLBCLdrug resistancePI3K/AKTSOX2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.